A New Way to Grow Tumors in 3-D

 ========= Old Image Removed =========Array
(
    [_wp_attached_file] => Array
        (
            [0] => 2018/03/BenchtopSystemCropped2.png
        )

    [_wp_attachment_metadata] => Array
        (
            [0] => a:5:{s:5:"width";i:558;s:6:"height";i:416;s:4:"file";s:34:"2018/03/BenchtopSystemCropped2.png";s:5:"sizes";a:8:{s:6:"medium";a:4:{s:4:"file";s:34:"BenchtopSystemCropped2-336x250.png";s:5:"width";i:336;s:6:"height";i:250;s:9:"mime-type";s:9:"image/png";}s:9:"thumbnail";a:4:{s:4:"file";s:34:"BenchtopSystemCropped2-140x140.png";s:5:"width";i:140;s:6:"height";i:140;s:9:"mime-type";s:9:"image/png";}s:9:"wbhm-icon";a:4:{s:4:"file";s:32:"BenchtopSystemCropped2-80x80.png";s:5:"width";i:80;s:6:"height";i:80;s:9:"mime-type";s:9:"image/png";}s:13:"wbhm-featured";a:4:{s:4:"file";s:34:"BenchtopSystemCropped2-558x338.png";s:5:"width";i:558;s:6:"height";i:338;s:9:"mime-type";s:9:"image/png";}s:18:"wbhm-featured-home";a:4:{s:4:"file";s:34:"BenchtopSystemCropped2-417x311.png";s:5:"width";i:417;s:6:"height";i:311;s:9:"mime-type";s:9:"image/png";}s:22:"wbhm-featured-carousel";a:4:{s:4:"file";s:34:"BenchtopSystemCropped2-355x265.png";s:5:"width";i:355;s:6:"height";i:265;s:9:"mime-type";s:9:"image/png";}s:28:"ab-block-post-grid-landscape";a:4:{s:4:"file";s:34:"BenchtopSystemCropped2-558x400.png";s:5:"width";i:558;s:6:"height";i:400;s:9:"mime-type";s:9:"image/png";}s:14:"post-thumbnail";a:4:{s:4:"file";s:34:"BenchtopSystemCropped2-125x125.png";s:5:"width";i:125;s:6:"height";i:125;s:9:"mime-type";s:9:"image/png";}}s:10:"image_meta";a:12:{s:8:"aperture";s:1:"0";s:6:"credit";s:0:"";s:6:"camera";s:0:"";s:7:"caption";s:0:"";s:17:"created_timestamp";s:1:"0";s:9:"copyright";s:0:"";s:12:"focal_length";s:1:"0";s:3:"iso";s:1:"0";s:13:"shutter_speed";s:1:"0";s:5:"title";s:0:"";s:11:"orientation";s:1:"0";s:8:"keywords";a:0:{}}}
        )

    [_imagify_optimization_level] => Array
        (
            [0] => 0
        )

    [_media_credit] => Array
        (
            [0] => 
        )

    [_navis_media_credit_org] => Array
        (
            [0] => Contributed photo
        )

    [_navis_media_can_distribute] => Array
        (
            [0] => 
        )

    [_imagify_data] => Array
        (
            [0] => a:2:{s:5:"sizes";a:9:{s:4:"full";a:5:{s:7:"success";b:1;s:8:"file_url";s:62:"https://news.wbhm.org/media/2018/03/BenchtopSystemCropped2.png";s:13:"original_size";i:334438;s:14:"optimized_size";i:294814;s:7:"percent";d:11.85;}s:9:"thumbnail";a:5:{s:7:"success";b:1;s:8:"file_url";s:70:"https://news.wbhm.org/media/2018/03/BenchtopSystemCropped2-140x140.png";s:13:"original_size";i:35756;s:14:"optimized_size";i:31300;s:7:"percent";d:12.460000000000001;}s:6:"medium";a:5:{s:7:"success";b:1;s:8:"file_url";s:70:"https://news.wbhm.org/media/2018/03/BenchtopSystemCropped2-336x250.png";s:13:"original_size";i:129448;s:14:"optimized_size";i:111378;s:7:"percent";d:13.960000000000001;}s:9:"wbhm-icon";a:5:{s:7:"success";b:1;s:8:"file_url";s:68:"https://news.wbhm.org/media/2018/03/BenchtopSystemCropped2-80x80.png";s:13:"original_size";i:13381;s:14:"optimized_size";i:11824;s:7:"percent";d:11.640000000000001;}s:13:"wbhm-featured";a:5:{s:7:"success";b:1;s:8:"file_url";s:70:"https://news.wbhm.org/media/2018/03/BenchtopSystemCropped2-558x338.png";s:13:"original_size";i:282733;s:14:"optimized_size";i:242232;s:7:"percent";d:14.32;}s:20:"wbhm-featured-square";a:5:{s:7:"success";b:1;s:8:"file_url";s:70:"https://news.wbhm.org/media/2018/03/BenchtopSystemCropped2-300x300.png";s:13:"original_size";i:135426;s:14:"optimized_size";i:116447;s:7:"percent";d:14.01;}s:18:"wbhm-featured-home";a:5:{s:7:"success";b:1;s:8:"file_url";s:70:"https://news.wbhm.org/media/2018/03/BenchtopSystemCropped2-417x311.png";s:13:"original_size";i:188737;s:14:"optimized_size";i:161523;s:7:"percent";d:14.42;}s:22:"wbhm-featured-carousel";a:5:{s:7:"success";b:1;s:8:"file_url";s:70:"https://news.wbhm.org/media/2018/03/BenchtopSystemCropped2-355x265.png";s:13:"original_size";i:142869;s:14:"optimized_size";i:122954;s:7:"percent";d:13.94;}s:14:"post-thumbnail";a:5:{s:7:"success";b:1;s:8:"file_url";s:70:"https://news.wbhm.org/media/2018/03/BenchtopSystemCropped2-125x125.png";s:13:"original_size";i:29236;s:14:"optimized_size";i:25640;s:7:"percent";d:12.300000000000001;}}s:5:"stats";a:3:{s:13:"original_size";i:1292024;s:14:"optimized_size";i:1118112;s:7:"percent";d:13.460000000000001;}}
        )

    [_imagify_status] => Array
        (
            [0] => success
        )

)
1665288136 
1520503344

If you can grow cancer outside the body, it’s easier to figure out how to kill it. With an eye toward faster drug development and more effective treatments, a UAB biomedical engineer has come up with a new way to sustain cancer cells. It’s a technical challenge, but Joel Berry knows how to explain his system in a digestible way:

“Think of it like making Jello at home.”

But instead of powder and water in a Jello mold for hungry people, it’s collagen in a silicone housing for hungry cancer cells.

“We put it all into a mold, and then we allow that collagen gel to actually form a solid,” says Berry. “And we keep everything profused with a nutrient fluid, and we keep it warm in an incubator, and it’s off to the races.”

Berry calls it a “bioreactor.” The collagen framework inside the housing is intricate, but the whole thing measures only about a cubic centimeter. “Cubic” is key: it’s three-dimensional, unlike, say, a single layer of cells in a petri dish. So the tumors can have volume, as they would in a person.

“We’re going for realism in that we’re creating a three-dimensional tumor, and we’re introducing a flow which is meant to mimic blood flow,” Berry says. “It’s allowed us to do a lot of different things with tumors on the bench-top.”

The engineering feat here is making tiny structures that can withstand fluid being pumped through them and sustain different kinds of cancer cells. Berry calls himself a “plumber,” but he’s a plumber who hopes to play a role in finding faster, cheaper ways to fight cancer.

These are not humans. So drugs that work on their cancers might not work in humans. But if you could grow someone's actual cancer cells...

Sarah Laval, Flickr
These are not humans. So drugs that work on their cancers might not work in humans. But if you could grow someone’s actual cancer cells outside that person and try out all sorts of drugs on it…

Zev Gartner, a pharmaceutical chemist at the University of California, San Francisco, points out that “it can cost anywhere from several hundred million to several billion dollars to develop and get new drugs approved by the pharmaceutical industry.”

He says the high costs and long duration of the process stem partly from drugs that show early promise – say, in mice – but later fail in expensive human trials. Gartner, who’s not affiliated with Berry’s work, says Berry’s bioreactors could cut those costs:

“One fantastic way of doing that would be to reduce the number of drugs that actually go into clinical trials that are likely to fail. And the best way of doing that is to have better models for the interaction of these drugs with humans.”

Along those lines, Gartner sees potential personalized benefits too. Sometimes drugs work for one person but not for someone else with the same kind of cancer. But, “one dream might be to be able to take a biopsy of a tumor and place it in a device and then screen say, 10, 20, maybe even a hundred different combinations of approved drugs and look to see which one works best. We might be able to actually take some of the guesswork out of what drugs to use.”

Berry says his team has made more than a hundred bioreactors and that cancer specialists at UAB are starting to use them in their own labs. If the system continues to work and spread, researchers could theoretically develop better treatments faster, and for less money.

 

At the Supreme Court, the case of the candidate who sued, even though he won

At issue was a suit by Rep. Michael Bost, R-Ill., challenging an Illinois regulation that allows ballots mailed in by Election Day to be counted for up to 14 days after polls close.

Israel and Hamas agree on the ‘first phase’ of Gaza ceasefire deal

The deal raises the possibility that the war may now be over, ending the bloodiest fighting ever between Israelis and Palestinians.

After Spain’s blackout, critics blamed renewable energy. It’s part of a bigger attack

When millions lost power in Spain and Portugal this spring, some were quick to blame too much solar and wind power. That wasn't the cause, but the misinformation had an impact.

‘Fairyland’ recalls a girl’s life with her poet father in pre-AIDS San Francisco

Alysia Abbott's memoir about growing up in 1970s San Francisco with her gay, single father, has been adapted into a film directed by Andrew Durham and produced by Sofia Coppola.

Los Angeles: Spaghetti Cumbia, a band born from cultural fusion

Photographers and storytellers Karla Gachet and Ivan Kashinsky document cumbia music in Colombia, Mexico, Ecuador, Peru, Argentina and the United States.

What are your holiday shopping plans? NPR wants to hear from you

Is this the season of cutbacks or splurges? As we prepare to cover holiday shopping and deals, NPR wants to hear from you, whatever your plans may be.

More Front Page Coverage